Correction to: Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.

This document is a correction to a study on the effectiveness of Dupilumab for the treatment of severe chronic hand eczema. The correction addresses an error in the layout of a table that provides baseline characteristics of the patients involved in the study. The corrected table includes important information on patient demographics, disease characteristics, and previous treatments. This correction ensures the accuracy of the study's findings and provides valuable information for researchers studying severe chronic hand eczema. [Extracted from the article]